ClinicalTrials.gg
WithdrawnNCT04401527Updated Sep 16, 2020

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

A Phase 2 interventional study of Sodium Nitrite and Normal Saline in COVID-19, Acute Respiratory Distress Syndrome and Acute Respiratory Failure, sponsored by Hope Pharmaceuticals. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Hope Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
No recruitment
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury and require mechanical ventilation.

Read the detailed description

This Phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury and require mechanical ventilation. The primary objective is to compare the two treatment groups with respect to the proportion of study subjects who are alive and free of respiratory failure at Day 28.

02

Conditions studied

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Acute Respiratory Failure

Keywords

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Acute Respiratory Failure
  • ARDS
  • Respiratory Failure
  • Intubation
  • Mechanical Ventilation
  • Intubated
  • Mechanical Ventilator
  • ECMO
  • Sodium Nitrite
  • Nitrite
  • Nitric Oxide
03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Hope Pharmaceuticals is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older;
  2. Diagnosed COVID-19 disease with confirmed SARS-coV-2 viral infection;
  3. Able to sign the form (ICF) or next of kin/legal guardian able to sign informed consent;
  4. Randomization within 24 hours of intubation and mechanical ventilation due to respiratory failure from COVID-19 infection;
  5. Absolute lymphocyte count > 800 / mm3;
  6. Women of (WCBP) must have a negative urine or serum (if anuric) pregnancy test at screening;
  7. WCBP must agree to abstain from sex or use an adequate method of from the time of informed consent through Day 28;
  8. Males must abstain from sex with WCBP or use an adequate method of contraception from the time of informed consent through Day 28.

Exclusion criteria

Exclusion Criteria:

  1. Methemoglobinemia > 2%;
  2. Hypotension with systemic blood pressure \< 90/60 mm Hg, or uncontrolled hypotension despite vasopressor support;
  3. History of sickle cell disease, thalassemia, G6PD deficiency, lung transplant, or allergy to sodium nitrite;
  4. \< 8 gm/dL;
  5. Renal impairment with \< 60 mL/min/1.73m2;
  6. Treatment within the past 48 hours with allopurinol (a medication that could interfere with nitrite metabolism);
  7. Treatment within the past 24 hours with organic nitrates such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, sodium nitroprusside, and inhaled nitric oxide;
  8. Treatment within the past 24 hours with lidocaine, prilocaine, benzocaine, and dapsone;
  9. Requiring extracorporeal membrane oxygenation (ECMO);
  10. Subjects with bacterial or fungal infections except for mild cutaneous infections or sinus infections;
  11. Subjects who are pregnant or lactating;
  12. Any condition that, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study;
  13. serious co-morbid medical conditions including, but not limited to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled chronic obstructive or chronic restrictive pulmonary disease, active central nervous system (CNS) disease uncontrolled by standard of care, known positive status for (HIV) (except if HIV subject has undetectable viral load and a of ≥ 500 cells/µL), and/or active or C, cirrhosis, or uncontrolled psychiatric illness/social situations that would limit compliance with study requirements;
  14. Treatment within 30 days or 5 half-lives of that agent (whichever is shorter) before the first study drug dose using another drug. Notwithstanding, prospective subjects who receive any of the following drugs or treatments before the first study drug dose or during this study may be considered for participation in this study: (1) a commercially available, FDA-approved drug or treatment used off-label for the treatment of COVID-19, or (2) a drug or treatment that has FDA Emergency Use Authorization for the treatment of COVID-19 patients;
  15. Moribund or not expected to survive 48 hours.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Sodium Nitrite

    Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.

    Drug: Sodium Nitrite

  • Placebo comparator
    Placebo

    0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.

    Drug: Normal Saline

Interventions

  • Continuous intravenous infusion of Sodium Nitrite Injection

    Also known as: Hope Pharmaceuticals Sodium Nitrite Injection USP 30 mg/mL

  • DrugNormal Saline

    Continuous intravenous infusion of Normal Saline

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Survival with Unassisted Breathing

    Proportion of study subjects who are alive and free of respiratory failure at Day 28

    Time frame: Day 28

Secondary outcomes

  1. Survival without Mechanical Ventilation

    Number of days alive without mechanical ventilation from start of study through Day 28

    Time frame: Day 28

  2. Survival without Intensive Care

    Number of days alive and not in the intensive care unit from start of study through Day 28.

    Time frame: Day 28

  3. Survival without Hospitalization

    Number of days alive and not in hospital from start of study through Day 28.

    Time frame: Day 28

  4. Survival without ECMO

    Alive on Day 28 and no use of ECMO therapy any time between start of study and Day 28.

    Time frame: Day 28

  5. Survival

    Alive on Day 28

    Time frame: Day 28

Other outcomes

  1. Lung Status

    Oxygenation index (PaO2/FIO2) at Day 14

    Time frame: Day 14

  2. Kidney Status (1)

    Blood urea nitrogen (BUN) at Day 14

    Time frame: Day 14

  3. Kidney Status (2)

    Creatinine at Day 14

    Time frame: Day 14

  4. Liver Status

    Liver function tests (ALT and AST) at Day 14

    Time frame: Day 14

07

Study locations

2 sites
  • Participating Research Facility
    Tampa, Florida 33606, United States
  • Participating Research Facility
    Fort Worth, Texas 76104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04401527
Lead sponsor
Hope Pharmaceuticals
Responsible party
Sponsor
First posted
May 26, 2020
Start date
Jul 22, 2020
Primary completion
Aug 15, 2020
Completion
Aug 15, 2020
Last update
Sep 16, 2020

Study contacts

Hope Pharmaceuticals Medical Director
study director · Hope Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Nitrite

Start the discussion